{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:11:26Z","timestamp":1779372686430,"version":"3.53.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.therap.2025.06.003","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:12:31Z","timestamp":1750677151000},"page":"270-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preventing the risk of tuberculosis with teriflunomide: Is pre-treatment screening necessary?"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5076-0698","authenticated-orcid":false,"given":"Marl\u00e8ne","family":"Damin-Pernik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Dautriche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Mazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Noelle","family":"Beyens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Botelho-Nevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2025.06.003_bib0075","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.neurol.2021.02.066","article-title":"Recommandations de la SFSEP \u00ab\u00a0Infections et scl\u00e9rose en plaques\u00a0\u00bb\u00a0: quel bilan pr\u00e9th\u00e9rapeutique\u00a0?","volume":"177","author":"Papeix","year":"2021","journal-title":"Rev Neurol"},{"key":"10.1016\/j.therap.2025.06.003_bib0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.therap.2022.03.001","article-title":"Pharmacovigilance and drug safety: fair prescribing and clinical research","volume":"77","author":"Montastruc","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.06.003_bib0085","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2174\/1570159X14666161208151525","article-title":"From leflunomide to teriflunomide: drug development and immunosuppressive oral drugs in the treatment of multiple sclerosis","volume":"15","author":"Aly","year":"2017","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.therap.2025.06.003_bib0090","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1586\/14737175.2014.962517","article-title":"How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?","volume":"14","author":"Fragoso","year":"2014","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.therap.2025.06.003_bib0095","doi-asserted-by":"crossref","first-page":"103184","DOI":"10.1016\/j.msard.2021.103184","article-title":"Latent tuberculosis infection reactivation in patients with multiple sclerosis in use of disease-modifying therapies: a systematic review","volume":"55","author":"Dantas","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.therap.2025.06.003_bib0100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/1744666X.2021.1886924","article-title":"Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment","volume":"17","author":"Otero-Romero","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.therap.2025.06.003_bib0105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.therap.2025.06.003_bib0110","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S1474-4422(21)00364-1","article-title":"Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial","volume":"20","author":"Chitnis","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.therap.2025.06.003_bib0115","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s12883-020-01937-4","article-title":"Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis","volume":"20","author":"Comi","year":"2020","journal-title":"BMC Neurol"},{"key":"10.1016\/j.therap.2025.06.003_bib0120","doi-asserted-by":"crossref","first-page":"e5866","DOI":"10.1002\/pds.5866","article-title":"Long-term safety of teriflunomide in multiple sclerosis patients: results of prospective comparative studies in three European countries","volume":"33","author":"Magyari","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2025.06.003_bib0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/1744666X.2019.1705785","article-title":"Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics","volume":"16","author":"Chiu","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.therap.2025.06.003_bib0130","unstructured":"Food and Drug Administration. AUBAGIO. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/202992s003lbl.pdf [accessed 19 June 2025 (29 pp.)]."},{"key":"10.1016\/j.therap.2025.06.003_bib0135","unstructured":"Food and Drug Administration. ARAVA. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020905s027lbl.pdf [Accessed 19 June 2025. (27 pp.)]."},{"key":"10.1016\/j.therap.2025.06.003_bib0140","unstructured":"EMA. Arava | European Medicines Agency. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/arava [Accessed 19 June 2025]."}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725000794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725000794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:36:51Z","timestamp":1779370611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595725000794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0040595725000794"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2025.06.003","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preventing the risk of tuberculosis with teriflunomide: Is pre-treatment screening necessary?","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2025.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}